Xeris Biopharma Holdings (XERS) Non-Current Deffered Revenue (2020 - 2022)

Xeris Biopharma Holdings has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $6.6 million in Q3 2022.

• For the quarter ending Q3 2022, Non-Current Deffered Revenue fell 2.65% year-over-year to $6.6 million; the trailing twelve-month figure through Sep 2022 stood at $6.6 million (down 2.65% YoY), and the FY2021 full-year result was $6.9 million, up 3.83% from the prior year.
• Non-Current Deffered Revenue for Q3 2022 stood at $6.6 million, down from $6.8 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $6.9 million in Q1 2022, with the low at $6.6 million in Q4 2020.
• Historically, Non-Current Deffered Revenue has averaged $6.8 million across 3 years, with a median of $6.8 million in 2021.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue gained 3.83% — and 2022, when it fell 2.65%.
• Xeris Biopharma Holdings' Non-Current Deffered Revenue stood at $6.6 million in 2020, then grew by 3.83% to $6.9 million in 2021, then retreated by 3.46% to $6.6 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $6.6 million (Q3 2022), $6.8 million (Q2 2022), and $6.9 million (Q1 2022), per Business Quant data.